Ani Solanki

This study shows that albumin-fused IL-10 reduces experimental autoimmune encephalomyelitis by enhancing immunoregulation in secondary lymphoid organs.

This paper introduces a 28-marker flow cytometry panel to profile cancer-associated fibroblasts (CAFs) and reveals their phenotypic and metabolic heterogeneity across different models.

This study develops a small-molecule approach to reduce prion protein by modulating pre-mRNA splicing, achieving ~70% PrP reduction in cells and demonstrating synergistic effects with a Luc7L activator in mice.

This paper develops a human-based translational activator to restore protein expression in a Dravet syndrome mouse model, showing improved survivability and seizure threshold.

This study develops a polymer-lipid hybrid nanoparticle (PLNP) to enhance mRNA delivery and T cell immunity, showing improved antigen-specific T cell responses and protection against viral variants and cancer.

This paper develops a targeted IL-10 therapy by fusing it with an LDL-binding antibody fragment, showing reduced vascular inflammation in atherosclerotic mice.

This study shows that an extracellular matrix coating similar to articular cartilage reduces myofibroblast differentiation and fibrosis in both in vitro and in vivo models.

This study shows that β-glucan-induced trained immunity in mice enhances antibody levels after vaccination by improving antigen presentation and T-cell responses.

The paper identifies a small molecule, A1155463, that induces trained immunity in macrophages without being immunogenic, enhancing anti-tumor resistance in mice.

The paper describes a method using engineered Flt3L to induce a tolerogenic immune state, reducing anti-drug antibodies to a fungal enzyme.